Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Gene coding error likely responsible for rare form of inherited 'short telomere' disease

Gene coding error likely responsible for rare form of inherited 'short telomere' disease

FDA approves first drug to treat patients with rare lung condition

FDA approves first drug to treat patients with rare lung condition

Rare inherited enzyme disorder offers new clues about fibrotic conditions

Rare inherited enzyme disorder offers new clues about fibrotic conditions

New target identified for treatment of idiopathic pulmonary fibrosis

New target identified for treatment of idiopathic pulmonary fibrosis

New statement highlights occupational burden of non-cancerous lung diseases

New statement highlights occupational burden of non-cancerous lung diseases

New chip-sized microscope focuses on super-resolution viewing

New chip-sized microscope focuses on super-resolution viewing

Research could provide a new way to treat organ scarring in future

Research could provide a new way to treat organ scarring in future

New findings from a safety and feasibility clinical trial on removal of senescent cells

New findings from a safety and feasibility clinical trial on removal of senescent cells

MUSC researchers identify potential therapeutic target for lung fibrosis

MUSC researchers identify potential therapeutic target for lung fibrosis

Researchers identify link between mucus in the small airways and pulmonary fibrosis

Researchers identify link between mucus in the small airways and pulmonary fibrosis

Middle-aged adults with lung disease may have greater risk of dementia later in life

Middle-aged adults with lung disease may have greater risk of dementia later in life

Researchers identify common genetic connection in lung conditions

Researchers identify common genetic connection in lung conditions

Veracyte to present data demonstrating potential of Envisia Genomic Classifier to improve ILD diagnosis

Veracyte to present data demonstrating potential of Envisia Genomic Classifier to improve ILD diagnosis

Study reveals long-term safety, efficacy of Ofev in patients with idiopathic pulmonary fibrosis

Study reveals long-term safety, efficacy of Ofev in patients with idiopathic pulmonary fibrosis

Cedars-Sinai receives $12 million from NIH to investigate deadly lung conditions

Cedars-Sinai receives $12 million from NIH to investigate deadly lung conditions

UA researchers receive $4.4 million grant to focus on idiopathic pulmonary fibrosis

UA researchers receive $4.4 million grant to focus on idiopathic pulmonary fibrosis

New guideline developed to help physicians diagnose idiopathic pulmonary fibrosis

New guideline developed to help physicians diagnose idiopathic pulmonary fibrosis

UAB receives NIH grant to continue evaluation of new medication for IPF

UAB receives NIH grant to continue evaluation of new medication for IPF

Scleroderma Foundation names Tulane professor as 'Doctor of the Year'

Scleroderma Foundation names Tulane professor as 'Doctor of the Year'

Gene therapy with telomerase does not increase cancer risk, study shows

Gene therapy with telomerase does not increase cancer risk, study shows